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httcense.Abstract Background/Aim: Hepatocellular carcinoma (HCC) is the most common primary malig-
nancy of the liver. Radioembolization with yttrium-90 (Y-90) microspheres is a new concept in radi-
ation therapy for HCC. The aim of this study is to evaluate efﬁcacy, side effects, and future
direction of Y-90 therapy, using TheraSphere, in patients with HCC with or without PVT.
Patients and methods: Forty patients were presented by hepatocellular carcinoma most of them
with portal vein thrombosis and were treated with Y-90 resin microspheres (SIR-TeX).
Results: At one month after treatment the overall response (complete or partial response) was
exhibited by 9% of patients, stable disease exhibited by 80% of patients, progressive disease seen
in 11% of patients.
Conclusion: Radioembolization with Y-90 resin microspheres offers a favorable risk/beneﬁt proﬁle
for patients presenting with locally advanced unresectable HCC with or without PVT and good
liver function.
 2013 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Hepatocellular carcinoma (HCC) is the most common primary
malignancy of the liver, it claims half a million lives across the
globe each year (1). It is the sixth most common cancer in the
world and is the third most common cause of cancer-related
mortality (2). Resection and transplantation are the only cura-
tive treatments at present. However, the role of surgery is
restricted. Resection can only be done in patients with
normal liver function and transplantation is only possible inProduction and hosting by Elsevier B.V.
.01.001
216 O.M. Hetta et al.patients who satisfy the Milan criteria (3). The only systemic
chemotherapeutic drug that has shown some potential in
managing HCC is Sorafenib (4).
Standard therapy for patients with larger tumor sizes and
no macrovascular invasion is transarterial chemoembolization
(TACE).
TACE has been shown to prolong the survival in patients
with BCLC (Barcelona clinic liver cancer) staging stage B
(intermediate stage), (5) But has failed to show survival ben-
eﬁt in patients with advanced HCC, even in those patients
with adequate hepatic functional reserve (6). Therefore, in
the current adaptation of the BCLC treatment algorithm
the therapy of choice for advanced HCC is systemic treat-
ment with sorafenib (7). This multikinase inhibitor has
recently been shown to prolong the survival in patients with
advanced HCC in a randomized, controlled phase III trial,
(8) and is the ﬁrst drug ever approved for the treatment of
HCC. Due to the adverse effect proﬁle of sorafenib, many
patients can only tolerate a reduced dose or must discontinue
the medication. This fact causes an ongoing effort to develop
a locoregional treatment approach to patients with advanced
HCC that is effective, but with a more acceptable/favorable
toxicity proﬁle than systemic therapy. Radioembolization
with yttrium-90 (Y-90) resin microspheres is an emerging
treatment for unresectable liver disease in patients who are
not amenable to liver transplantation, resection, or selective
ablative techniques (e.g., radiofrequency ablation or percuta-
neous ethanol injection) (9,10). The microspheres loaded with
Y-90 are delivered to liver tumors by means of endovascular
catheters selectively placed within the hepatic arterial vascula-
ture (11).
The therapeutic advantage of the hepatic arterial approach
is based on the unique dual vascular supply of the liver. It is
known that hepatic tumors receive 80%–100% of afferent
blood exclusively from the hepatic artery. Radioembolization
takes advantage of this to provide liver-directed transarterial
therapy (12).
The microspheres lodge preferentially within the neovessels
of the tumor(s) and deliver high-energy radiation over a lim-
ited range (mean penetration of radiation into tissues is
2.4 mm), thereby minimizing the radiation exposure to normal
liver parenchyma (11). Radioembolization differs substantially
from transarterial chemoembolization (TACE). In TACE, the
occlusion of medium and large size arteries (with the use of
particles 3–10 times larger than those used in radioemboliza-
tion) results in tumor ischemia that drives an antitumor effect,
with drug delivery potentially enhancing tumor cell killing
(13).
Radioembolization has two distinct aspects of the
procedure: the ﬁrst being the injection of embolic particles
(‘‘embolization’’) as the vehicle and the second being the deliv-
ery and administration, via this embolic vehicle, of radiation
(‘‘radio’’).
Hence, in patients presenting with PVT, there is a concern
of an increased risk of liver failure as a result of the preexistent
reduction of portal ﬂow and the incremental compromise of
arterial hepatic perfusion caused by the embolization of micro-
spheres in the hepatic micro- and macrovessels. As a result,
Y-90 microsphere therapy has historically been contraindi-
cated in patients presenting with PVT (14,15). Recent studies
with Y-90 glass microspheres have suggested that the original
safety concerns regarding the risk of hepatic compromise inpatients presenting with PVT may have been unfounded (16).
An intense embolizing effect of glass microspheres has been
recently ruled out by analyzing the pattern of arterial blood
ﬂow after contrast agent power injection immediately after
treatment (17).
2. Patients and methods
Forty patients with unresectable HCC were referred from Clin-
ical Oncology Department to be treated by radioembolization
using Y-90 resin microspheres (SIR-TeX) during a period of
12 months between August 2011 and August 2012 at Ain
Shams specialized hospitals.
Inclusion criteria for treatment included (1) HCC by imag-
ing or pathology (2) nonsurgical candidate; not ﬁt for radiofre-
quency or TACE (3) noncompromised pulmonary function
(assessed by the history of severe chronic obstructive pulmon-
ary disease, physical examination, and auscultation); (4) able
to undergo angiography and selective visceral catheterization;
(5) Portal vein thrombosis has been regarded as a relative con-
traindication to such treatments as TACE; however, it is not
necessarily a contraindication to radioembolization; (6) tumor
less than 70% of the total liver volume (5) adequate hematol-
ogy (granulocyte countP 1.5 · 109/L, plateletsP 50 · 109/L),
renal function (creatinine 6 2.0 mg/dL); (6) liver function (bil-
irubin 6 2.0 mg/dL).
Exclusion criteria were (1) other planned therapy systemic/
locoregional therapy for their cancer; (2) liver failure (biliru-
bin > 2.0 mg/dL); (3) evidence of any uncorrectable ﬂow to
the gastrointestinal tract observed on angiography or techne-
tium-99m macroaggregated albumin scan; (4) greater than
30 Gy (16.5 mCi) estimated to be delivered to the lungs in a
single administration or 50 Gy on multiple administrations;
and (5) signiﬁcant extrahepatic disease. Of note, patients were
not excluded from therapy on the basis of portal hypertension
or hepatofugal ﬂow.2.1. Treatment protocol
 Patients underwent a planning angiographic study to iden-
tify vascular anatomy, HCC feeding vessels, aberrant ves-
sels and extrahepatic collateral vessels feeding extrahepatic
organs (especially the gastrointestinal tract), and the pres-
ence of intrahepatic or intratumoral arterioportal shunting.
 Aberrant hepatic vessels and extrahepatic collaterals were
coil-embolized to prevent the inadvertent misplacement of
Y-90 resin microspheres into the gastrointestinal tract or
pancreas. Technetium Tc 99m–labeled MAA particles were
then injected with the delivery catheter in the intended posi-
tion for Y-90 resin microsphere infusion.
 The major approach for the delivery of microspheres was
lobar infusion, although segmental application of micro-
spheres had to be used occasionally to prevent visceral
shunting. If a bilobar infusion of Y-90 microspheres was
planned, this was performed sequentially and the time
between both treatments was 3–4 weeks.
 All the patients underwent 99mTc-MAA planar imaging to
assess pulmonary shunt and any unintended ﬂow to other
extra-hepatic organs. An elevated hepatopulmonary shunt
leading to exposure of the lungs of > 30 Gy in a single
Table 1 Baseline characteristics for the examined patients.
Characteristics Value
Sex-n (%)
Male 25(71)
Female 10(29)
Median age of therapy – mean(±SD) years 58(8)
Portal vein thrombosis n (%) 34(97)
Main PVT 7(20)
Right PVT 13(37)
Left PVT 9(26)
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in extrahepatic abdominal locations was exclusion criteria
for therapy with radioembolization.
 Dosimetry was calculated to maximize the therapeutic
activity to tumorous tissue and minimize the exposure of
non-tumoral parenchyma and lung tissue. Within 2 weeks
of the planning angiography study, the prescribed activity
of Y-90 resin microspheres was administered by placing
the tip of the delivery catheter in the same anatomic posi-
tion as that used for the 99mTc-MAA injection. Treatment
protocol was approved institutionally.Segmental PVT 5 (14)
Child–Pugh status – n (%)
A 24(68)
B 11(32)
BCLC stage – n (%)
Stage A 0(0)
Stage B 1(3)
Stage C 34(97)
ECOG Performance Status – n (%)
0 18(51)
1 15(43)
2 2(6)
Previous HCC treatment n (%) 29(82)
Surgical resection 3(11)
TACE 10(35)
RF 8(27)
TACE+ RF 8(27)
Albumin – median (range) [g/dL] 3.3(2.5–4.2)
Total bilirubin – median (range) [mg/dL] 0.9 (0.5–3)
Alpha-fetoprotein – median (range) [ng/mL] 200(2–500)
0–100 n (%) 3(8)
100–400 n (%) 10(29)
>400 n (%) 22(63)
Table 2 Assessment of tumor radiological response at 30 days
after radioembolization with Y-90 microspheres.
Radiological response n (%)
WHO criteria
Complete or partial response 3(9)
Stable disease 28(80)
Progressive disease 4(11)
WHO with EASL modiﬁcation
Complete response 3(8)
Partial response 11(32)
Stable disease 18(52)
Progressive disease 3(8)2.2. Radiological evaluation of tumor response
Assessment for tumor response was performed at 1 month
following initial treatment. World Health Organization
(WHO) tumor response on imaging was determined for mea-
surable lesions (>1 cm) by using the cross-product of perpen-
dicular diameters. ‘‘Complete response’’ was deﬁned as a
change in the sum of the cross-products to zero (in other
words, a 100% reduction), ‘‘partial response’’ as a decrease
in the sum of cross-products by at least 50%, ‘‘stable disease’’
as a decrease in the sum of cross-products by less than 50%
or an increase less than 25%, and ‘‘progression’’ as an in-
crease in the sum of cross-products by at least 25%. The
European Association for the Study of Liver Disease (EASL)
modiﬁcation of WHO was also implemented. Tumors exhib-
iting signiﬁcant lack of enhancement (>50% necrosis) and
reduction in vascularity following treatment were categorized
as EASL-responders (18).
3. Results
3.1. Patient characteristics
Table 1 represents the baseline characteristics of the ﬁnally
treated patients (35) and their diseases who underwent radio-
embolization with Y-90 microspheres.
3.2. Demographics and disease staging
Thirty ﬁve patients were ﬁnally treated, 5 patients were ex-
cluded after MAA scan due to high pulmonary shunt. The
mean age at the time of therapy was 58 years (±4 years). All
the patients have liver cirrhosis, liver disease was classiﬁed
by Child Pugh score, 68% of patients are child A and 32%
are child B classiﬁcation, child C patients are not included in
the study. All the patients have ECOG (The Eastern Cooper-
ative Oncology Group) score 0–2, 51% with performance 0,
43% with performance 1 and 6% with performance 2. Most
of the patients have portal vein thrombosis (97%), 20% with
main PVT, 37% with right PVT, 26% with left PVT
(Fig. 2A) and 14% with segmental PV thrombosis. Alfa-feto
protein was elevated above 400 ng/dl in 63%, between 100–
400 ng/dl in 29% and below 100 ng/dl in 8%.3.3. Tumor response
As shown in Table 2, according to the WHO criteria complete
or partial response was exhibited by 9% of patients (Figs. 1and 4), stable disease exhibited by 80% of patients, progressive
disease seen in 11% of patients. When the EASL modiﬁcation
of WHO was incorporated in response (tumor necrosis and
lack of enhancement/vascularity by > 50%) (Figs. 2 and 3),
complete response was noted in 8% of patients, partial re-
sponse in 32% of patients, stable disease was exhibited by
52% of the patients, whereas 8% of patients demonstrated dis-
ease progression following treatment.
Fig. 1 Female patient, 50 years old, with right hepatic lobe focal lesion (segment V) measuring about 5 cm that shows enhancement in
arterial phase (1A, 1B). After radioembolization, the lesion decreased in size and became necrotic, with no enhancement (1C, 1D).
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Clinically, side effects encountered after radioembolization
were: 11 cases (31%) with vague self limiting abdominal pain
and fatigue, one case each of pleural effusion and hepato-renal
syndrome. No cases of radiation induced pneumonitis or gas-
tritis. There were no cases of technical related treatment re-
lated mortality.
Liver related side effects, irrelevant changes in the liver
function were noted at 30 days. Two patients (5%) developed
hepatic encephalopathy, three patients (8%) developed asci-
tes, and no differences were observed in prothrombin activity.
Regarding total bilirubin, a statistically signiﬁcant but clini-
cally irrelevant increase was observed after radioemboliza-
tion, 10 patients (28%) had increased bilirubin level with
median values of 0.9 mg/dL at baseline and 1.2 mg/dL at
30 days.4. Discussion
Radioembolization has emerged over the last decade as a loco-
regional treatment option for HCC.
Radioembolization, as a kind of brachytherapy, has a dif-
ferent treatment mechanism from embolization. Microspheres
laden with the beta-emitting isotope Y-90 are infused directly
through a catheter into the hepatic artery; they are small en-
ough to pass deep into the tumor vasculature but too large
to pass through the capillary bed and reach venous circulation,
preventing deposition in the lungs (19).One advantage of this treatment option is that Y-90 radio-
embolization can be performed in an unselective fashion. In
contrast to TACE, the rate of adverse effects after such ‘‘unse-
lective’’ application, as performed over the main or lobar
branch of the hepatic artery, is not signiﬁcantly increased as
compared to segmental or even subsegmental microsphere
application, although the tumor response rate may vary
(20,21).
The introduction of radioembolization for the treatment
of patients with HCC and PVT has been tempered by con-
cerns regarding the potential increased risk of liver failure,
complications, and death as a result of impairment of hepa-
tic vascular supply in the presence of compromised portal
blood ﬂow (15,16). These concerns have been driven by
the previous experience with intense embolic therapies such
as chemoembolization. If there was an incremental effect
of signiﬁcant impairment of hepatic arterial blood ﬂow in
concern with preexisting portal ﬂow compromise, one would
expect three possible scenarios after radioembolization: (i)
postembolization syndrome resulting from tumor ischemia;
(ii) altered liver function resulting from minor but sustained
reduction in vascular supply to nontumorous tissue; or (iii)
acute ischemic hepatitis resulting from severe, immediate
reduction in vascular supply. None of these clinical phenom-
ena have been observed in these patients with PVT who
were treated with Y-90 resin microspheres, although the
slight increase in serum bilirubin may reﬂect a subclinical
embolic effect.
Our study represents the initial experience describing the
use of Y-90 glass microspheres as a locoregional treatment in
Fig. 2 Male patient 60 years old with left hepatic lobe inﬁltrative HCC (segments II, III) with enhancement in the arterial phase (2A, 2B)
and ﬁlling of left portal branch denoting its invasion (2C). After radioembolization the lesion became necrotic, hypodense with no contrast
enhancement and non-ﬁlling of the left portal branch in arterial phase.
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thrombosis and have no other treatment options i.e. resection,
radiofrequency or TACE.
As regards the post-radioembolization overt adverse ef-
fects, the most frequent symptoms reported were transient fa-
tigue syndrome and abdominal pain (31%), which have been
reported by other investigators to be the most common ad-
verse reaction after therapy with Y-90 resin microspheres
(22,23).Increased bilirubin level has been shown to be a good indi-
cator of overall hepatic function. Nevertheless, our study
showed only a mild increase at 1 month after treatment,
which would suggest an absence of clinically relevant ische-
mia-induced effect. Indeed, this same phenomenon is
observed in patients with PVT who are treated with Y-90
microspheres and could reﬂect a subtle effect of radiation.
A study of treatment with Y-90 resin microspheres in 37
patients with PVT (22) indicated a posttreatment increase in
Fig. 4 Male patient 68 years old showing an ill-deﬁned hypovascular HCC at right hepatic lobe (segment VI) (4A, 4B). After
radioembolizaiton, the tumor became shrunken and necrotic (4C, 4D).
Fig. 3 Male patient, 63 years old showing right hepatic lobe inﬁltrative HCC (segment VI) with contrast enhancement in the arterial
phase (3A, 3B). After radioembolization, the tumor became hypodense with no enhancement in the arterial phase and decreased in size
(3C, 3D).
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of branch PVT cases and 58% of main PVT cases. Clinically
detectable posttreatment ascites (Southwest Oncology Group
grade 2–4) was evident in 8% of branch PVT cases and
50% of main PVT cases, yet in our study only three patients
(8%) presented with ascites after procedure. The authors
attributed the higher incidence of liver-related events in the
main PVT group to their more advanced disease stage and
worsened prognosis (22).
Severe AEs that may be associated with radioembolization
are radiation pneumonitis and gastrointestinal ulcerations.
They are caused by the unintentional deposition of micro-
spheres either through tumor-associated arteriovenous shunt-
ing into the lungs, or by way of collateral vessels to the
intestine originating in the hepatic arterial system. Pneumoni-
tis is now generally considered a rare event in Y-90 micro-
sphere treatment, as the introduction of the pretreatment
Tc99-MAA scan, and the deﬁnition of maximal lung doses,
has made it increasingly unlikely (24,25). Radiation pneumo-
nitis or gastrointestinal ulceration was not observed in our
study due to careful selection and pretreatment diagnostic
work-up.
The efﬁcacy of radioembolization in our study was sup-
ported by the classical WHO criteria as well as those modiﬁed
by the EASL group (18). The overall response was 9%, when
necrosis (>50%) was incorporated in the assessment of re-
sponse, the response rate increased to 40%. However, previous
analyses have shown that a survival beneﬁt in HCC may be im-
parted by therapies with positive tumor responses (26).
Although the EASL response rate in this cohort was not as
high as other reports of liver-directed therapies (for example,
radiofrequency ablation), it is important to recognize that this
cohort did include patients with inﬁltrative and multifocal dis-
ease, large tumors, and PVT. These are generally excluded
from other therapies (such as radiofrequency ablation), and
hence a direct comparison of treatment response to these ther-
apies is not possible. Larger tumors of the inﬁltrative type are
unlikely to respond by size or necrosis criteria.
Our present study is a short term preliminary study con-
cerned with the technical efﬁcacy of radioembolization in the
treatment of unresectable HCC rather than a long term fol-
low-up study. However, we followed up the patients at
3 month interval by cross-sectional imaging during the study
period and will further continue this follow-up to prepare for
a subsequent long term follow-up and survival rate study.5. Conclusion
From our limited experience, it appears that radioemboliza-
tion with Y-90 resin microspheres offers a favorable risk/
beneﬁt proﬁle for patients presenting with locally advanced
unresectable HCC with or without PVT and good liver func-
tion. Unlike other embolic therapies such as chemoemboliza-
tion, radioembolization appears to be an effective treatment
for patients who otherwise have limited treatment options
and present with a poor prognosis. Further prospective clin-
ical studies are required to validate the ﬁndings from our
small patient sample and to evaluate the patient survival
as well as the results of combination of radioembolization
with sorafenib.References
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